Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04588363 · ClinicalTrials.gov registry record
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 244
- Enrollment target
NCT04588363: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT04588363 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 244 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04588363 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 244 participants
- Enrollment target
Study Summary
The primary objectives of this study are: * To determine the proportion of children with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) related death, rehospitalization or major complications after infection with SARS-CoV-2 and/or Multisystem Inflammatory Syndrome in Children (MIS-C), and * To determine immunologic mechanisms and immune signatures associated with disease spectrum and subsequent clinical course during the year of follow-up.
Primary Outcome
Participants who experience Coronavirus Disease 2019 (COVID-19)-related death, rehospitalization or major complications after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) illness and/or multisystem inflammatory syndrome in children (MIS-C).
Interventions
- OTHER SARS-CoV-2 and/or MIS-C Exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2020-11-19 |
| Est. Completion | 2023-03-03 |
What the finished NCT04588363 record still lists
NCT04588363 is an observational study that tracks outcomes without assigning an intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which SARS-CoV-2 and/or MIS-C Exposure is the first listed.
NCT04588363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04588363 about?
NCT04588363 is a clinical study titled "COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C". The primary objectives of this study are: * To determine the proportion of children with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) related death, rehospitalization or major complications after infection with SARS-CoV-2 and/or Multisystem Inflammatory Syndrome in Children (MIS-C),...
What is the current status of trial NCT04588363?
This trial is currently completed. The enrollment target is 244 participants. The study started on 2020-11-19. Estimated completion is 2023-03-03.
What interventions are being tested in trial NCT04588363?
The interventions under investigation include: SARS-CoV-2 and/or MIS-C Exposure (OTHER).
Who is sponsoring clinical trial NCT04588363?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI